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1. Introduction
Prostate  cancer  is  the  most  common  form  of  cancer  in  men  in  the  United  Kingdom
(UK).  A  quarter  of  all  new  cases  of  cancer  diagnosed  in  men  are  prostate  cancers.  In
2009,  over  40,000  cases  of  prostate  cancer  were  reported  in  the  UK  and  more  than
10,000  men die  from the  disease  each  year  [1].  Prostate  cancer  is  also  a  major  concern
worldwide.  Its  highest  incidence  rates  are  found  in  Australia  and  New  Zealand  with
its lowest in South-Central  Asia [2].
The  rate  of  men  being  diagnosed  with  prostate  cancer  has  significantly  increased
worldwide  in  recent  decades  [3].  This  is  likely  due  to  the  prostate-specific  antigen  test
being performed among younger men and resulting in the majority of  men being diag‐
nosed  with  localised  prostate  cancer  (LPCa)  [4,  5].  These  men  are  usually  presented
with  treatment  options,  which  most  commonly  include:  (1)  active  surveillance  (i.  e.  ,
regular  monitoring of  disease  activity  for  those  intended to  be  treated with  subsequent
curative  treatment),  (2)  radical  prostatectomy,  (3)  external  beam  radiation  therapy,  and
(4)  brachytherapy,  and  are  asked  to  consider  and  select  their  preferred  treatment.  The
situation  that  patients  with  LPCa  face  is  somewhat  unique.  They  have  to  decide  be‐
tween treatments because there is  no substantial  evidence to suggest that one treatment
modality  differs  from other  treatments,  in  terms of  overall  survival  rate  [6,  7].  Howev‐
er,  there  are  considerable  differences  in  the  side-effects  associated  with  each  treatment
option.
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2. Treatment side-effects and their psychological impact
Men confronted with this treatment decision often need to take into consideration a range of
factors, including the potential physical side effects of treatments and their psychological,
social and emotional consequences. For example, patients being treated with radical thera‐
pies can experience severe side-effects, such as urinary incontinence (UI) and erectile dys‐
function (ED), as a result of treatment. UI symptoms can persist years after treatment [8] and
this can have an impact on all aspects of an individual’s functioning. Men with UI often
avoid social situations due to the risk of their incontinence becoming apparent to other peo‐
ple. They can feel embarrassed by their inability to self-control their bodily functions and by
the lack of empathy from other people within social situations [9].
Relatively little research has been conducted to examine the relationship between ED and
psychological morbidity among men with prostate cancer. Nevertheless, ED has been re‐
ported to have a profound effect on a patient’s quality of life post-treatment. Nelson et al.
[10] examined the relationship between depressive symptoms and erectile function. A group
of men, who did not receive any treatment for their prostate cancer, completed self-report
questionnaires measuring anxiety and depression symptoms and erectile function approxi‐
mately 4-years post-diagnosis. Erectile dysfunction was found to be a significant predictor
of depression independent of other influential factors of depression, such as anxiety and
marital status. This finding suggests that men can experience lasting psychological effects
from their disease. Another study by Nelson et al. [11] examined men’s responses to ED af‐
fecting their sexual function and their adjustment to diminished erections after having un‐
dergone a radical prostatectomy. These men completed self-report questionnaires
measuring erectile function and sexual satisfaction pre-operatively, 12 and 24 months post-
operatively. The findings revealed that sexual satisfaction decreased after surgery with pa‐
tients feeling ashamed and embarrassed by their difficulty to perform sexually with their
partners. Sexual dissatisfaction persisted over the period of 24-months, even in men who re‐
ported good erectile function post-operatively. Thus, it appears that men do not seem to ad‐
just well to the consequences of their treatment.
ED is a condition which not only affects the individual but also affects couples. There have
been differences in the perceptions held by men with ED due to treatment for prostate can‐
cer and their partners. Men with ED have reported an “all or nothing” approach to their sex‐
ual relationship with their partner; in that if they are unable to ‘perform’ sexually then it is
pointless to engage in sexual contact. This can lead to men withdrawing from intimate con‐
tact with their partners causing strain on the relationship [12]. Women partners have report‐
ed to be less concerned about treatments to help the physical functioning of their partners
with ED, and are more focused on finding alternative ways to maintain intimacy and sexual
stimulation [13].
The option of active surveillance as a management plan for LPCa can also affect the quali‐
ty  of  life  of  men diagnosed with the  disease.  Although no active  treatment  is  adminis‐
tered,  active  surveillance  can  have  a  psychological  impact.  Qualitative  studies  have
provided some insight  into  the  experiences  of  living with prostate  cancer.  For  instance,
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Hedestig et al. [14] conducted interviews with patient with untreated LPCa and analysed
the interview transcripts  using in-depth qualitative narrative analysis.  Their  findings re‐
vealed that men perceived their disease as life-threatening, experienced uncertainty, fear
and worry about their cancer progression, and a repressed sense of manhood due to sexu‐
al dysfunctions.
3. Personal beliefs and treatment selection
The decision on a treatment modality for LPCa could, therefore,  be described as a chal‐
lenging  one  requiring  patients  to  weigh  up  a  range  of  physical  and psychological  out‐
comes  of  treatments.  Indeed,  it  has  been  shown  that  patients  can  experience  decision-
related  distress  at  diagnosis,  which  can  persist  over  time  and  lead  to  poorly  informed
treatment decisions [15]. The difficulties associated with making a treatment choice can be
further  magnified  by  patients  making  their  decisions  based  on  their  personal  beliefs.
These personal beliefs can help patients construct a mental representation about their dis‐
ease and its treatment, which can guide their adjustment to their disease. Such beliefs are
of particular importance to treatment decisions when there is great uncertainty around the
long-term effects of treatment.
Extensive research has found that personal beliefs can predict a range of outcomes, includ‐
ing quality of life, help-seeking behaviour and treatment adherence [16-18]. These beliefs
have also been shown to affect treatment choice, mainly by way of selecting between con‐
ventional treatment and complementary and alternative medicines (CAM) for conditions,
such as chronic pain, hypertension, and both localised and advanced prostate cancer [19-22].
These studies reported that patients who used CAM were more likely to hold negative be‐
liefs about their illness (i. e. , that their illness was chronic and that they had little personal
control over its management); and about conventional treatments (i. e. , believed the treat‐
ments would result in significant undesirable side-effects). In contrast, patients who were
less likely to favour CAM held positive beliefs about their illness and its treatment (i. e. , be‐
lieved the condition was not severe and would easily be controlled with conventional treat‐
ment). Indeed, patients’ positive beliefs about their illness were also shown to increase the
likelihood of choosing generic rather than branded medicines, as well as reduce the amount
of drugs they consumed to manage their conditions [20, 23].
It is not well-understood how patients, who are diagnosed with LPCa and offered conven‐
tional treatments, make sense of their disease and their treatment decisions through examin‐
ing personal beliefs. Patients with LPCa can make treatment decisions that may not
necessarily be in accordance with the treatment-related information provided by urologists
[24]. Thus, patients may choose a treatment based on confounding information derived from
their own experience and from other sources available to them. By gaining a better under‐
standing of patients’ personal beliefs may help both patients and urologists make more in‐
formed decisions about treatments.
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4. A systematic review of the literature
An initial scope for existing literature reviews in prostate cancer research yielded two re‐
views [25, 26]. The more recent review [26] was conducted five years ago and restricted its
search period to a 14 year time span, used a small number of literature databases and only
searched for original, peer-reviewed studies to explore broadly the personal (not just beliefs
specifically) and external factors pertaining to the decision-making process of patients. It
concluded that there is a general lack of understanding about the role of patients’ beliefs in
treatment selection and that this was an area worthy of enquiry. Our aim was, therefore, to
provide an updated review on factors influencing treatment selection for LPCa, as well as
specifically examine the literature pertaining to patients’ personal beliefs about LPCa and/or
its treatments.
A systematic search of the literature was conducted in electronic databases to retrieve rele‐
vant published papers from 1980 – 2010, which included: MEDLINE (1950-present); CI‐
NAHL; ScienceDirect and CancerLIT (PubMed). Searches were conducted by exploding and
combining the medical subject term ‘prostate cancer’ and free-text words, such as ‘beliefs,
cognitions, choices, treatment options’. A language restriction was not set whilst searching
for the papers.
Non-scholarly literature was searched using the following charity databases: The Prostate
Cancer Charity (Jan-April 2010) and Cancer Research UK. The following Government web‐
sites were also searched: World Health Organisation (WHO) and the National Institute of
Health and Clinical Excellence (NICE). The Networked Digital Library of Theses and Disser‐
tations was searched for theses discussing relevant work and studies.
The reference lists of literature reviews were hand-searched and key authors identified from
the search procedure were contacted for any other relevant studies.
The studies retrieved from the literature searches were screened against the inclusion crite‐
ria, which included: (i) samples of men diagnosed with, and being treated for, LPCa, and (ii)
studies examining patients’ beliefs about their LPCa and treatment options. All study de‐
signs except reviews, opinion papers and single case studies, were considered for inclusion
into the present review.
The titles and abstracts of the references yielded from the search procedure were screened
against the inclusion criteria. The full text of the potentially relevant papers were retrieved
and read for consideration into the review. The papers that met the inclusion criteria were
assessed for their methodological quality.
5. Synthesis of findings
The search procedure yielded ten papers, which are summarised in Tables 1 and 2. It was
inappropriate to combine findings statistically to produce meaningful outcomes. This was
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partly due to the small number of quantitative studies identified for inclusion into the re‐
view. Primarily, the assessment of the included studies revealed there to be many meth‐
odological  differences  that  existed  between  the  studies.  This  made  it  difficult  to  pool
studies to determine the effect of perceptions on treatment selection. Therefore, a qualita‐
tive synthesis of  the findings was undertaking with studies being grouped according to
treatment modality and those factors  affecting decision-making.  Statistical  findings from
the quantitative studies were used to support the observed findings from the qualitative
studies.
5.1. Beliefs underpinning treatment selection for localised prostate cancer
5.1.1. Radical prostatectomy
Patients’ beliefs and other influences in selecting to undergo a radical prostatectomy were
clearly reported in nine of the studies [27-35]. Many of the patients perceived their cancer as
a localised problem and that the most tangible and definitive method of curing or prevent‐
ing the disease from spreading was to remove the tumour [27-29, 31, 35]. These findings
were also replicated in three of the quantitative studies, which reported that beliefs about
the effectiveness of surgery and complete tumour removal were statistically associated with
selecting surgery [33-35]. Surgery would also allow for surgeons to be more informed about
the nature and extent of the cancer and would provide the patients with more information
about their disease [27, 28]. Surgery was considered to have the best evidence base in terms
of its efficacy in combating cancer compared to other curative treatment options [31, 32].
Overall, patients believed surgery to be the best and most effective form of treatment. This
corresponds with current treatment rates, which show that the majority of patients with
LPCa opt for surgery [36].
5.1.2. External beam radiation therapy and brachytherapy
External beam radiation therapy (EBRT) was regarded by most patients as being an inferior
treatment option to a radical prostatectomy. This was based on their belief that EBRT pro‐
vided uncertainty surrounding its ability to cure their cancer [27, 28, 30, 31] through treat‐
ment administered externally to the body. Unlike a radical prostatectomy, EBRT was
believed to disadvantage the patient by being time-consuming and disruptive to daily life
with severe consequential side-effects [27, 28]. Interestingly, some of these side-effects were
mistaken for side-effects associated with chemotherapy (e. g. , hair loss, weight loss, vomit‐
ing) [27, 28, 30]. It appeared that when patients selected EBRT as their preferred treatment, it
was to avoid the negative effects of surgery, i. e. , being less invasive and resulting in fewer
side-effects [31, 35]. These beliefs were similar to those held by patients who selected bra‐
chytherapy as their preferred treatment. However, like a radical prostatectomy, brachyther‐
apy was believed to provide a ‘direct’ and, therefore, more effective and convenient form of
treatment to cure their cancer [31, 34].
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5.1.3. Active surveillance / watchful waiting
The terms ‘watchful waiting’ were used in some of the papers along with the other ac‐
tive  treatment  options.  Watchful  waiting  usually  refers  to  a  less  intense  management
plan where palliative care is  usually provided. These options were rarely considered by
patients as a management option for their cancer. They were typically rejected due to pa‐
tients’  fear  about the cancer spreading [31,  33]  and their  need to be “doing something”
active to combat their prostate cancer [28, 31]. Holmboe and Concato [31] suggested that
other possible explanations for patients rejecting watchful waiting included fear of death
or the inability to monitor cancer progression. Patients who opted for active surveillance
perceived  their  cancer  as  ‘a  very  small  growth’  and a  common disease  among men as
they  get  older.  These  men were  accepting  of  the  uncertainty  surrounding  their  disease
progression  and believed it  would  be  best  to  endure  the  severe  side-effects  of  curative
treatment only when it was evident that treatment was required [37]. However, this will‐
ingness to accept active surveillance as a management option appeared to occur in men
whose  urologists  advocated the  view that  the  disease  was  not  severe  and would prog‐
ress slowly [37].
Study
Ref
Authors, year, & study
location
Design Characteristics of
sample
Major findings
[27] Denberg et al. (2006)
Denver, USA
Perspective cohort
(follow-up 6-8 months)
using semi-structured
interviews
20 men newly
diagnosed with LPCa
considering treatment
options
Age range 53-80 years
70% (white); 25%
(African American); 5%
(Latino)
40% perceived surgery as a
definitive treatment
Surgery offered crucial
knowledge about tumour
55% perceived surgery as
undesirable regarding
invasiveness
[28] O’Rourke (1999)
North Carolina, USA
Perspective cohort
(follow-up 3 & 12
months) using couple &
individual semi-
structured interviews
18 men newly
diagnosed with LPCa
who have made a
treatment decision
18 spouses recruited
Mean age 67.6 (range
52-78 years) (patient)
Mean age 62.1 (range
49-74 years) (partner)
13% white (patient),
5% African American;
72% white, 28% African
American (spouse)
Couples believed cancer is
only curable through
surgery
Perceived uncertainty
about radiotherapy
regarding efficacy &
outcome
Men more concerned
about side-effects than
wives
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Study
Ref
Authors, year, & study
location
Design Characteristics of
sample
Major findings
[29] O’Rourke & Germino. (1998)
North Carolina, USA
Retrospective cross-
sectional study using
unstructured focus
groups
11 men diagnosed with
LPCa, who have made a
treatment decision
6 spouses recruited
Age range 58-72 years
(patients)
Age range 51-64 years
(spouses)
99% white; 1% African
American
Surgery perceived as a first
line choice
Prior bias toward surgery
due to perceived
association with cure
Radiotherapy perceived
inferior to surgery due to its
efficacy & side-effects
[30] Steginga et al. (2002)
Queensland, Australia
Cross-sectional study
using semi-structured
interviews
108 men diagnosed
with LPCa considering
curative treatment
options
Mean age 62 years
(range 39-80 years)
Ethnicity not specified
47% described other
patients’ treatment
experiences used in their
decision-making
34% held lay belief that
surgery was the best way to
cure their cancer
12% were uncertain about
radiotherapy as a way to
cure their cancer
[31] Holmboe & Concato. (2000)
New Haven, USA
Cross-sectional study
using interviews with
open-ended questions
102 men newly
diagnosed with LPCa,
who have made a
treatment decision
Mean age 66.4 years
Majority white (89%)
Majority influenced by
external information (i.e.,
30% for physician
recommendation)
Classified likes & dislikes of
treatments
Removal of tumour &
evidence of efficacy as main
likes for surgery
Fear of future
consequences was the most
common reason to reject
watchful waiting
[37] Davison et al. (2009)
Vancouver, Canada
Retrospective cross-
sectional study using
interviews with semi-
structured interviews
25 men with low-risk
prostate cancer on
active surveillance
Mean age 66 years
(range 48-77 years)
Majority white (92%);
8% South Asian
Men perceived their cancer
as a common disease &
exaggerated the potential
incidence
Realised treatment might
be necessary, but viewed as
“a grey zone"
Table 1. Description of the Qualitative Studies included in the Systematic Review
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Study ID
reference
Authors, year, &
study location
Design Characteristics of sample Major findings
[32] Hall et al. (2003)
Virginia, USA
Retrospective cross-
sectional study using self-
report questionnaires
developed from literature
review & clinical
impressions
351 men with LPCa treated with
surgery or brachytherapy
Mean age 62±5 years (radical
prostatectomy); 66±8 years
(brachytherapy); 70±7 years
(combination of brachytherapy &
radiotherapy)
Ethnicity not specified
42.9% brachytherapy patients &
97.5% radical prostatectomy
patients chose treatment based on
evidence shown to cure the cancer
Side-effects were an important
motivator
Urologists were the most
important source of information
and a major factor in decision-
making process
[33] Zeliadt et al. (2010)
USA
Cross-sectional study
using self-report
questionnaires developed
from preliminary focus
groups & cognitive
interviews
198 newly diagnosed patients
considering surgery only &
patients considering other
treatment options
Mean age 63 years
72% white, 11% black, 16%
Hispanic/Asian (surgery); 68%
white, 26% Black, 6% Hispanic/
Asian (other options)
Treatment efficacy influenced
preference for surgery
Personal burden influenced
nonsurgical options
[34] Gwede et al. (2005)
Florida, USA
Cross-sectional study
using questions derived
from previous study
69 men diagnosed with LPCa,
who have made a decision about
treatment
Mean age: 57.7 years (range
39.6-71.1) (surgery); 65.2 years
(range 45.7-89.2)
(brachytherapy)
86.5% (surgery); 97%
(brachytherapy) white
Cure and complete tumour
removal were the main
motivations for surgery (74%)
Brachytherapy related to quality-
of-life issues
[35] Teramoto et al. 2006
Kamogawa, Japan
Cross-sectional study
using self-report
questionnaires
51 men diagnosed with LPCa
treated with radical
prostatectomy or external beam
radiation therapy
Overall mean age: 68.2 (range
56–75 years)
Japanese sample
Physician was the major factor
influencing treatment decisions in
both treatment groups (>90%)
Family and others was a more
important factor for patients
undergoing surgery than patients
undergoing radiation therapy
Surgery was desired for cancer
control
Radiation therapy favoured
concerning side-effects
Table 2. Description of the Quantitative Studies included in the Systematic Review
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5.1.4. The role of urologists and partners in informing patient beliefs
The recommendations made by urologists emerged in many of the papers [28, 29, 31-33,
37]  as  being  influential  in  shaping  patients’  beliefs  regarding  their  treatment  choice.  A
high percentage of patients (48-65%) said they would selected the treatments recommend‐
ed by their  urologist  [30,  32].  Consequently,  seeking a  second opinion was unnecessary
serving only to delay treatment and provide potentially more conflicting information to
process [27, 28].
Partners, who often experience considerable emotional distress themselves on hearing the
diagnosis [25, 38], have also been found to exert an important influence on patients’ beliefs.
Three studies reported the role of the partners to be a source of information or a mediator in
helping men to process their treatment information [27, 32, 34]. However, it was also report‐
ed in two studies that, ultimately, it is the patients themselves who reported ownership of
their treatment decision [29, 37].
5.1.5. The role of patients’ information seeking behavior in informing beliefs
Another major factor influencing patients’ beliefs was their own information-seeking behav‐
iour. Patients and their partners are often actively engaged in learning about their treatment
options, side-effects and the background of their urologists [29]. The evidence suggested
that they made use of a variety of resources, including health care professions (HCPs) (i. e. ,
urologists, radiation oncologist), the internet, books, magazines, friends and family [27, 29,
30, 32, 34, 37]. Processing such large amounts of advice and potential contradictory informa‐
tion was suggested to be an explanation for the misconceptions about treatments reported
by the patients (i. e. , associating the effects of chemotherapy with radiotherapy) [27, 30].
5.1.6. The role of other patients’ treatment experiences in informing patient beliefs
In four studies, there was evidence that patients [27, 28, 30, 33] and their partners used the
experiences of other people with cancer in their decisions about treatment. Denberg et al.
[27] described that these experiences influenced patients’ beliefs regarding LPCa, its treat‐
ment and treatment side-effects. Steginga et al. [30] reported that 47% of men described con‐
sidering other people they knew (not just those with prostate cancer), who had negative
experiences with cancer or cancer treatment, in their decision-making. O’Rourke [28] report‐
ed that comparisons with other patients, who had a positive outcome from treatment, were
mostly related to surgery and that comparisons were usually made between friends and
family members, who had undergone surgery and were making a good recovery. It has
been suggested that patients may pay more attention to the experiences of other patients
with cancer than to the risk information presented to them by their urologists and specialist
nurses [27]. The reliability of their findings was supported by the quantitative findings of
Zeliadt et al. [33], who reported a statistically significant association between the experien‐
ces from other patients and treatment selection for patients who only considered surgery as
a viable treatment.
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6. Discussion
The findings synthesised in the present review have demonstrated that patients select a
treatment or management option based on their beliefs about their cancer, the perceived ef‐
fectiveness of the treatment and their beliefs regarding the side-effects of the treatment.
With regards to the present findings, the majority of patients select active surveillance be‐
cause of their belief that their cancer was not aggressive, selected to undergo a radical pros‐
tatectomy because they believed it to be most effective at curing their cancer, and selected
EBRT because of the reduced risk of side-effects. A range of factors external to the patient,
which inform these beliefs, were also identified. These included the patients’ high regard of
the urologists’ treatment recommendation, the emotional distress experienced by partners,
the various modes of seeking information about treatments, and other peoples’ experiences
of treatment.
It is, however, also very clear that the evidence base on patients’ beliefs in the context of
LPCa remains limited. This is an area in need of high quality prospective studies to gain a
greater understanding of the factors that influence treatment decisions. This understanding
could help develop interventions designed to support men in these decisions and to assist
with their long-term adjustment to prostate cancer and its treatment.
The limited evidence that has been synthesised in this review does, however, enable some
clear recommendations to be made how this area of research and, ultimately, clinical prac‐
tice may move forward. In particular, it is clear that the existing findings relate well to two
theoretical frameworks, which have been developed to understand patients’ beliefs regard‐
ing illness and treatment; and which have also been the basis of therapeutic interventions
[39, 40]. These are the self-regulatory model (SRM) [41, 42] and the Necessity Concerns
Framework (NCF) [17, 43]. The SRM describes that individuals’ personal beliefs allow them
to make sense of their disease and enable them to reach their illness goals (e. g. , in LPCa
these could be survival, reducing the risk of side effects, etc. ). These beliefs cluster around 5
domains: (1) identity (the way patients describe their disease and its symptoms); (2) cause
(what caused the disease); (3) timeline (how long the disease is going to last); (4) conse‐
quence (how will the disease and/or its treatment affect me?); and (5) controllability (wheth‐
er the disease is believed to be preventable, curable, or controllable). Similarly, the NCF also
focuses on personal beliefs, but those specifically related to treatment. Previous research has
shown that patients’ beliefs regarding treatment tend to focus on two domains: beliefs re‐
garding how necessary/important the treatment is to their future well-being and beliefs re‐
garding concerns (i. e. , what are the potential adverse consequences of the treatment?).
There was clear evidence in the studies included in this review of the beliefs specified by
both the SRM and NCF. For example, patients believed their cancer to be a mass within the
body (akin to identity beliefs) and that removing this mass would cure their cancer (akin to
controllability beliefs). Similarly, patients believed curative treatment would offer them the
best outcome in terms of survival (akin to necessity beliefs) because their cancer could po‐
tentially re-occur (akin to concern beliefs). Furthermore, the importance of factors external to
the patient in shaping their beliefs is also specified by the SRM. Thus, it was suggested that
Advances in Prostate Cancer72
the results of this review provide strong evidence to support the use of these theoretical
frameworks in future research.
7. Recommendation for health care
It is clear that the use of patients’ beliefs in their decisions on a treatment modality has led
them to base their decisions on misconceptions rather than on evidential information. HCPs
may need to challenge misinformed beliefs held by patients to help them make more in‐
formed decisions regarding their treatment. In order to make more conclusive recommenda‐
tions for health care practice, further research is required to establish the extent to which
personal beliefs alter treatment selection.
8. Recommendations for further research
The majority of the studies included in this review used a qualitative approach. Such meth‐
ods explore a topic area in-depth and provide a descriptive account of findings. While this
approach can provide very rich data in specific domains, these data are not intended to be
generalisable. Thus, quantitative studies (preferably with prospective designs) are required
in the future to ascertain, not only the salient beliefs influencing treatment choices but also,
how these beliefs affect long-term adjustment to the disease and its treatment.
With regards to the studies which employed quantitative methodologies, none used stand‐
ardised and validated measures for examining illness or treatment beliefs. Two of the quan‐
titative studies [32, 34] developed their measures of beliefs from previous published work.
The remaining study developed its measure from preliminary focus groups and interviews
[33]. It could be suggested that further validation of these measures is required before any
strong conclusions can be drawn.
The time at which illness and treatment beliefs were measured is another shortcoming of the
included studies. Some of the studies included those patients who had already made a treat‐
ment decision or who had already started treatment. This may have affected the reliability
of the findings due to the potential bias of patients recalling what they believed about their
illness and its treatment at these times in the treatment process. Prospective designs involv‐
ing the assessment of beliefs before a treatment choice is made would offer a more robust
approach.
A further limitation concerned the majority of the patient samples being predominantly
white and from North America. Therefore, the experiences of other groups, such as men of
Afro-Caribbean origin in whom the risk of prostate cancer is greater, were not represented.
Further research is required across a range of ethnic and cultural groups.
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9. Conclusion
The present review has revealed that our understanding of the role played by the personal
beliefs of men regarding their LPCa and its treatment is still limited. The existing evidence
has been dominated by qualitative methods, cross-sectional designs and the use of non-vali‐
dated instruments. However, it is also clear from existing findings that the adoption of the
SRM and NCF, with their associated validated instruments, could provide a greater under‐
standing of the factors that influence treatment decisions. Further research using psycholog‐
ical frameworks could also help develop interventions to support men in their treatment
decisions, and assist with their long-term adjustment to LPCa and its treatment.
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